Home Cart Sign in  
Chemical Structure| 29868-97-1 Chemical Structure| 29868-97-1

Structure of Pirenzepine 2HCl
CAS No.: 29868-97-1

Chemical Structure| 29868-97-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pirenzepine 2HCl is a is an anticholinergic agent and induces the dimerization of muscarinic M1 receptors, used to treat myopia, gastric and duodenal ulcers.

Synonyms: Gastrozepin dihydrochloride; Pirenzepin dihydrochloride; Gastrozepin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pirenzepine 2HCl

CAS No. :29868-97-1
Formula : C19H23Cl2N5O2
M.W : 424.32
SMILES Code : O=C1C2=CC=CC=C2N(C(CN3CCN(C)CC3)=O)C4=NC=CC=C4N1.[H]Cl.[H]Cl
Synonyms :
Gastrozepin dihydrochloride; Pirenzepin dihydrochloride; Gastrozepin
MDL No. :MFCD00055214
InChI Key :FFNMBRCFFADNAO-UHFFFAOYSA-N
Pubchem ID :71405

Safety of Pirenzepine 2HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK 293 cells 4–400 nM 30 minutes Investigation of the binding kinetics of Bodipy-pirenzepine to EGFP-fused M1 receptors, revealing a biphasic binding process involving fast and slow binding steps. J Biol Chem. 2009 Jul 17;284(29):19533-43

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rhesus monkeys Normal rhesus monkeys and monkeys with implanted electrodes Subconjunctival injection 0.0002% to 2% Single injection, observed for 70 minutes To study the effects of Pirenzepine on pupil diameter, static and dynamic accommodation. Results showed that after 2% Pirenzepine injection, pupil diameter significantly increased, static accommodation significantly decreased, and nearly complete cycloplegia occurred. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3620-8
White Leghorn chicks Negative-lens-induced myopia model Intravitreal injection 0.2 μmol Once daily for 4 days To investigate the effect of pirenzepine at different times of administration on inhibiting myopia development, found that noon administration was most effective Exp Eye Res. 2019 Apr;181:5-14
Female C57 Bl/6J mice Streptozotocin-induced diabetic mice model Topical application to the hind paw 0.2%, 1.0%, 2.0%, 10.0% 20 min/day, 5 days/wk for 8 weeks To evaluate the preventive and reversal effects of topical pirenzepine on peripheral neuropathy in diabetic mice. Results showed that 2.0% pirenzepine prevented thermal hypoalgesia and loss of epidermal nerve fibers, while 10.0% dose also prevented motor nerve conduction velocity slowing. J Pharmacol Exp Ther. 2020 Jul;374(1):44-51
Guinea pigs Anesthetized guinea pigs Intravenous injection 1-100 nmol/kg Every 2 minutes To study the effect of pirenzepine on bronchoconstriction and bradycardia elicited by vagal nerve stimulation and ACh. Results showed that low doses of pirenzepine increased vagally-induced bronchoconstriction, while higher doses blocked postjunctional receptors. Br J Pharmacol. 1989 Jun;97(2):499-505

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.36mL

0.47mL

0.24mL

11.78mL

2.36mL

1.18mL

23.57mL

4.71mL

2.36mL

References

 

Historical Records

Categories